Compare RES & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RES | PCRX |
|---|---|---|
| Founded | 1984 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | N/A | 2011 |
| Metric | RES | PCRX |
|---|---|---|
| Price | $5.68 | $26.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $5.24 | ★ $32.86 |
| AVG Volume (30 Days) | ★ 1.6M | 723.2K |
| Earning Date | 01-29-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.22 | ★ 0.47 |
| Revenue | ★ $1,536,150,000.00 | $716,791,000.00 |
| Revenue This Year | $16.11 | $6.24 |
| Revenue Next Year | $5.05 | $9.53 |
| P/E Ratio | ★ $26.07 | $55.78 |
| Revenue Growth | ★ 4.20 | 3.14 |
| 52 Week Low | $4.10 | $18.17 |
| 52 Week High | $7.17 | $27.64 |
| Indicator | RES | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.47 | 72.55 |
| Support Level | $5.73 | $23.63 |
| Resistance Level | $5.96 | $24.81 |
| Average True Range (ATR) | 0.16 | 0.93 |
| MACD | 0.02 | 0.25 |
| Stochastic Oscillator | 67.90 | 100.00 |
RPC Inc is an oilfield services company. It provides specialized oilfield services and equipment to independent and oil and gas companies engaged in the exploration, production, and development of oil and gas properties throughout the United States. The company's operating segment includes Technical Services and Support Services. It generates maximum revenue from the Technical Services segment. Technical Services segment nclude RPC's oil and gas services that utilize people and equipment to perform value-added completion, production and maintenance services directly to a customer's well. Support Services segment consists of drill pipe and related tools, pipe handling, pipe inspection and storage services, and oilfield training and consulting services.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.